Sourceunknowntext stored

Recent Publications & Key Insights on Residual Risk

Author not recordedDate not recordedOriginal︎ ↗Archived copy

Claims1

ExaminationsNone

Text293 sections

VersionsOne known

CopiesNone recorded

CorrectionsNone recorded

Facts checked Nov 9, 2026

ReachNo copies recorded

StructureIn 1 claim's map0 sources downstream across 1 claim

EvidenceNot yet read

ReviewsNot reviewed

Examinations

None recorded. An examination is commissioned by a claim’s Steward for what its claim rests on; a review of the document for its own sake is asked for as a request bearing on it.

Text503 passages · 1 marked

No examination yetMarked passage

Subscribe0 passages

Home0 passages

About The Initiative0 passages

About R3i0 passages

Governance0 passages

The Jean-Charles Fruchart Prize0 passages

Educational Content0 passages

Booklets0 passages

Slidekits Library0 passages

Webinars0 passages

Talks0 passages

Video series0 passages

Resources0 passages

R3i Editorials0 passages

R3i Focus0 passages

R3i Landmarks0 passages

Relevant Publications On Residual Risk0 passages

R3i Publications0 passages

Events0 passages

Relevant Publications on Residual Risk1 passage

Latest Publications0 passages

20260 passages

Five insights from ESC Congress 20263 passages

Key words: Atorvastatin; older adults, STAREE; disability-free survival0 passages

REACT: Silent atherosclerosis starts earlier than expected3 passages

Key words: Silent atherosclerosis; imaging; prevalence; REACT trial5 passages

Key words: Residual inflammatory risk; pacibekitug; TRANQUILITY trial; interleukin-60 passages

SHASTA-3 and SHASTA-4: Promising results with plozasiran11 passages

VESALIUS-REAL: The gap between evidence and practice3 passages

Key words: VESALIUS-CV trial; primary prevention; evolocumab; mortality2 passages

Key words: VESALIUS-CV trial; primary prevention; total cardiovascular events; evolocumab7 passages

Key words: VESALIUS-REAL; lipid management; goal attainment; gender disparities2 passages

Key words: Lipoprotein(a); Lp(a); lipid management; registry6 passages

Key words: Evolocumab; PCSK9 inhibition; Immediate treatment of acute MI0 passages

More Publications0 passages

20260 passages

Global challenge of cardiovascular-kidney-liver-metabolic disease1 passage

View publication0 passages

Longer-term data for zodasiran in mixed hyperlipidemia6 passages

View publication4 passages

Key words: Olezarsen; hypertriglyceridemia; fibrates; efficacy0 passages

View publication0 passages

Inflammation in low-risk individuals4 passages

Key words: Inflammation; C-reactive protein; low cardiovascular risk; Copenhagen General Population Study0 passages

View publication0 passages

Remnant cholesterol in cardiovascular-kidney-metabolic syndrome4 passages

Key words: Remnant cholesterol; cardiovascular-kidney-metabolic syndrome0 passages

View publication0 passages

Lipoprotein(a) and residual cardiovascular risk6 passages

Keywords: Lipoprotein(a); Lp(a); threshold; cardiovascular risk0 passages

View publication0 passages

More insights from VESALIUS-CV trial5 passages

View publication0 passages

Ruvonoflast, novel anti-inflammatory therapy5 passages

Key words: NLRP3 inflammasome; residual inflammatory risk; ruvonoflast; atherosclerotic cardiovascular disease0 passages

View publication0 passages

POSEIDON highlights global burden of high inflammatory risk6 passages

Key words: Inflammatory risk; atherosclerotic cardiovascular disease; chronic kidney disease; global prevalence0 passages

View publication0 passages

Meta-analysis of ANGPTL3 inhibitors5 passages

Key words: Angiopoietin-like protein 3 (ANGPTL3) inhibitors; meta-analysis; triglycerides; lipids0 passages

View publication0 passages

Prognostic thresholds for Lp(a) may differ by race/ethnicity4 passages

Key words: Lipoprotein(a); NHANES; risk stratification; race; ethnicity; thresholds0 passages

View publication0 passages

HDL anti-inflammatory capacity and residual cardiovascular risk5 passages

Key words: HDL function; anti-inflammatory capacity; residual cardiovascular risk0 passages

View publication0 passages

Gemilukast: combined lipid-lowering and anti-inflammatory effects3 passages

Key words: Gemilukast; anti-inflammatory; lipid-lowering; residual cardiovascular risk0 passages

View publication1 passage

Ez-PAVE demonstrates cardiovascular benefit of lower LDL-C target5 passages

Key words: Intensive lipid lowering; low-density lipoprotein cholesterol target; guidelines0 passages

CORALreef AddOn: Oral PCSK9 inhibitor Enlicitide vs. oral non-statin therapies4 passages

Key words: Oral PCSK9 inhibitor; enlicitide; CORALreef AddOn trial1 passage

Lp(a) and CAC Predict CV Risk3 passages

Key words: Lipoprotein(a); coronary artery calcium; risk stratification5 passages

Key words: Lipoprotein(a); overweight treatment guidelines; atherosclerotic cardiovascular disease0 passages

View publication0 passages

Remnant cholesterol and residual stroke risk in atrial fibrillation4 passages

Keywords: ARIC; atrial fibrillation; remnant cholesterol; stroke0 passages

View publication5 passages

Key words: Metabolic dysfunction–associated steatotic liver disease; MASLD; acute coronary syndrome0 passages

View publication0 passages

Insights into residual cardiovascular risk in the Arabian Gulf region5 passages

View publication0 passages

Target both lipoprotein(a) and inflammation to reduce residual risk4 passages

Key words: Lipoprotein(a); interleukin-6; inflammation; residual cardiovascular risk; UK Biobank0 passages

View publication0 passages

High residual inflammatory risk in PCI patients5 passages

Key words: Residual inflammatory risk; percutaneous coronary intervention; MACE0 passages

View publication0 passages

Semaglutide in peripheral artery disease5 passages

Key words: Semaglutide; glucagon-like peptide-1 receptor agonists; peripheral artery disease-0 passages

View publication0 passages

Bempedoic acid in metabolic dysfunction-associated steatotic liver disease6 passages

View publication0 passages

Pemafibrate shows efficacy in statin-intolerance5 passages

Key words: Pemafibrate; statin-intolerance; selective PPARα modulator0 passages

View publication0 passages

Lipoprotein(a) in risk assessment4 passages

Key words: Lipoprotein(a); Cardiovascular risk assessment; Cardiovascular mortality; All-cause mortality0 passages

View publication0 passages

DA VINCI: target triglycerides to improve lipid goal attainment4 passages

Key words: Goal attainment; non-HDL-C; Triglyceride-rich lipoproteins; DA VINCI0 passages

View publication0 passages

ANGPTL8 linked with atherosclerosis in type 2 diabetes4 passages

Key words: ANGPTL8; Angiopoietin-Like Protein 8; Type 2 diabetes; Residual cardiovascular risk0 passages

View publication0 passages

Novel treatments in the news0 passages

TLC-2716: oral liver-restricted LXR inverse agonist3 passages

View publication0 passages

SHR-1918: Another ANGPTL3 antibody for Homozygous Familial Hypercholesterolemia3 passages

Key words: Homozygous familial hypercholesterolemia; ANGPTL3; Monoclonal antibody0 passages

View publication3 passages

Key words: Neratinib; Inflammation; Atherosclerosis0 passages

View publication0 passages

20250 passages

Zodisiran in homozygous familial hypercholesterolemia1 passage

View publication0 passages

Missed opportunities to target elevated apolipoprotein B due to high remnant cholesterol4 passages

View publication0 passages

ZEUS: targeting interleukin-6 in chronic kidney disease2 passages

View publication0 passages

Screen early for inflammation, cholesterol and lipoprotein(a) to prevent stroke4 passages

Key words: Stroke; inflammation; Women’s Health Study; primary prevention0 passages

View publication0 passages

Benefits of olezarsen in severe hypertriglyceridemia6 passages

Key words: Olezarsen; ApoC3; severe hypertriglyceridemia; triglycerides; pancreatitis0 passages

View publication0 passages

DR10624: novel agent for severe hypertriglyceridemia5 passages

Key words: DR10624, severe hypertriglyceridemia; metabolic dysfunction-associated steatotic liver disease0 passages

Enlicitide: a novel oral PCSK9 inhibitor5 passages

Key words: Enlicitide; oral PCSK9 inhibitor; CORALreef Lipids Trial0 passages

Genetic modelling supports cardiovascular risk reduction with APOC3 silencing5 passages

View publication0 passages

Higher remnant cholesterol tracks higher myocardial risk after stenting3 passages

Key words: remnant cholesterol; PCI; major adverse cardiovascular outcomes; ischemic events0 passages

View publication7 passages

View publication0 passages

More insights from REDUCE-IT2 passages

Key words: icosapent ethyl; REDUCE-IT; myocardial infarction subtypes0 passages

View publication3 passages

Key words: Triglyceride-rich lipoproteins; remnants; atherosclerosis; outcomes trials; mechanisms; review0 passages

View publication0 passages

Residual inflammatory risk in type 1 diabetes: REC1TE trial3 passages

Keywords: cardiovascular; colchicine; residual inflammatory risk; type 1 diabetes0 passages

View publication0 passages

Remnant cholesterol contributes to cardiovascular risk reduction with LDL-C lowering therapies4 passages · 1 marked

Low-density lipoprotein cholesterol (LDL-C) is undoubtedly causal for atherosclerotic cardiovascular disease and therefore the priority for preventive lipid lowering therapy. However, it is also recognised that non-LDL lipids are associated with cardiovascular risk. This study tested whether reduction in remnant cholesterol contributes to the cardiovascular risk reduction observed in statin, ezetimibe, and PCSK9 inhibitor trials.

Chronic inflammation and insulin resistance are primary drivers of atherosclerosis independent of LDLContradicteddenies

Not yet read by this claim’s Steward.

View publication0 passages

NHANES shows trend for decreasing prevalence of high remnant cholesterol4 passages

View publication0 passages

Low-grade inflammation and elevated remnant cholesterol in impaired renal function4 passages

View publication4 passages

View publication0 passages

From the European Atherosclerosis Society Congress, 4-7th May 2025, Glasgow, UK0 passages

Favourable results with obicetrapib2 passages

View publication3 passages

View publication0 passages

First in-human data for novel ANGPTL4 inhibitor5 passages

View publication6 passages

View publication0 passages

Lowering remnant cholesterol and ASCVD reduction4 passages

View publication0 passages

Remnant cholesterol and cardiovascular-kidney-metabolic syndrome4 passages

View publication0 passages

New review: Genetics of remnant cholesterol2 passages

View publication0 passages

Remnant cholesterol, inflammation and cardiovascular risk: insights from the EPIC-Norfolk study2 passages

View publication0 passages

Elevated remnant cholesterol contributes to cardiovascular events in diabetes2 passages

View publication0 passages

Remnant cholesterol in the elderly4 passages

View publication0 passages

Latest news from the OCEAN(a)-DOSE trial with olpasiran5 passages

View publication0 passages

Obstructive sleep apnoea, acute coronary syndrome and remnant cholesterol4 passages

View publication0 passages

20245 passages

View publication0 passages

Study links high remnant cholesterol with dementia risk6 passages

View publication0 passages

Diabetes-related macrovascular complications increase risk of microvascular complications: UK Biobank study5 passages

View publication0 passages

Women still receive suboptimal lipid lowering therapy post-MI3 passages

View publication0 passages

PALISADE demonstrates efficacy of plozasiran in familial chylomicronemia syndrome6 passages

View publication0 passages

ANGPTL3 siRNA Zodasiran in mixed hyperlipidemia4 passages

View publication0 passages

Pemafibrate in Metabolic dysfunction-associated steatotic liver disease4 passages

View publication0 passages

Inflammatory risk in polyvascular disease4 passages

View publication0 passages

Semaglutide in patients with type 2 diabetes and chronic kidney disease3 passages

View publication0 passages

Residual inflammatory risk in ischaemic stroke2 passages

View publication0 passages

Inclisiran in people with diabetes or obesity2 passages

View publication0 passages

High remnant cholesterol prevalent in Mexicans3 passages

View publication0 passages

Stagnating risk factor control in US4 passages

View publication0 passages

AEGIS-II trial fails to impress4 passages

View publication0 passages

Remnant cholesterol, triglycerides and risk of cardiometabolic morbidity6 passages

View publication0 passages

Obicetrapib in Japanese patients4 passages

Harada-Shiba M, Davdison MH, Ditmarsch M, et al1 passage

View publication6 passages

View publication0 passages

NHANES: Heterogeneity of dyslipidaemia in diabetes5 passages

View publication0 passages

Lipoprotein(a) and residual cardiovascular risk4 passages

Arnold N, Blaum C, Goßling A, et al1 passage

View publication0 passages

Remnant cholesterol: a residual risk factor for aortic valve calcium progression6 passages

View publication0 passages

20230 passages

High long-term residual risk: Act earlier2 passages

Front Cardiovasc Med 2024; DOI 10.3389/fcvm.2023.13081730 passages

View publication0 passages

Increasing stroke burden in Asia3 passages

Zhang X, Lv H, Chen X, et al1 passage

View publication0 passages

Prediabetes, MACE, and adverse limb events4 passages

Hsu J-C, Yang Y-Y, Chuang S-L, et al1 passage

View publication0 passages

RICO registry: elevated triglycerides and residual risk of recurrent ischaemic events7 passages

View publication0 passages

Remnant cholesterol and risk of premature mortality6 passages

View publication0 passages

Remnant cholesterol and metabolic disorders5 passages

View publication6 passages

Circulation 2023; doi: 10.1161/CIRCULATIONAHA.123.066398. Online ahead of print0 passages

View publication0 passages

Remnant cholesterol linked with chronic kidney disease severity6 passages

View publication0 passages

More insights from REDUCE-IT3 passages

Szarek M, Bhatt DL, Miller M, et al0 passages

View publication0 passages

Preclinical data with novel APOC3 inhibitor3 passages

View publication0 passages

Novel ANGPTL3 inhibitor6 passages

Nat Med 2023; doi: 10.1038/s41591-023-02494-20 passages

View publication0 passages

ORION-8: largest trial to date with inclisiran, targeting PCSK96 passages

View publication0 passages

Statin use and risk for recurrent stroke1 passage

Association of statin use with risk of stroke recurrence after intracerebral hemorrhage0 passages

Gaist D, Rodríguez LAG, Hallas J, et al0 passages

Neurology 2023; DOI: https://doi.org/10.1212/WNL.00000000002077920 passages

View publication0 passages

New ESC guidelines4 passages

View publication0 passages

Escalating cost of cardiovascular disease in Europe2 passages

Luengo-Fernandez R0 passages

View publication0 passages

Higher remnant cholesterol linked with bioprosthetic valve degeneration6 passages

View publication0 passages

Pemafibrate in non-alcoholic fatty liver disease5 passages

Life 2023;13:1327. https://doi.org/10.3390/life130613270 passages

View publication0 passages

News from the SUSTAIN 6 and PIONEER 6 trials with semaglutide6 passages

View publication3 passages

Kraaijenhof JM, Opstal TSJ, Cornel JH, et al0 passages

Arterioscler Thromb Vasc Biol 2023; DOI: 10.1161/ATVBAHA.123.3192720 passages

View publication0 passages

Remnant cholesterol and all-cause death in heart failure3 passages

Predictive value of remnant cholesterol for all-cause mortality in heart failure patients2 passages

View publication0 passages

Triglyceride-rich lipoproteins associate with early in-stent neointimal atherosclerosis formation6 passages

View publication0 passages

Higher remnant cholesterol increases mortality risk5 passages

Wadström BN, Pedersen KM, Wulff AB, Nordestgaard BG1 passage

View publication0 passages

Remnant cholesterol and cardiovascular disease4 passages

Eur J Prev Cardiol 2023;zwad036. doi: 10.1093/eurjpc/zwad0360 passages

View publication0 passages

Nonalcoholic fatty liver disease in Chile5 passages

View publication8 passages

View publication0 passages

20150 passages

Contact0 passages

Legal Notice0 passages

Follow0 passages

Follow1 passage

English2 passages

Lineage across 1 claim

Draws on · none recorded

This source

Recent Publications & Key Insights on Residual Risk

in 1 claim's map

Drawn on by · none recorded

Record

Kind: unknown
Authors: Not recorded
Publisher: Not recorded
Published: Not recorded
DOI: None
Link: https://r3i.org/recent-publications-on-residual-risk/
Archived copy: https://web.archive.org/web/20250315153239/https://r3i.org/recent-publications-on-residual-risk/
Stored text: 222,228 characters, retrieved Aug 7, 2026 · 293 sections, 503 passages
Claims extracted: Not recorded
Versions: One known
Copies: None recorded
Corrections: None recorded
Facts checked: Nov 9, 2026

History 2

Nov 9, 2026FactsFacts fetcher · Facts looked up
Aug 7, 2026Entered the graphEntered the graph; no copy stored